Cytoki Pharma ApS Financials, key figures and credit report
Gross profit -42 198.7 kDKK FY 2025 -7.8% vs 2024
EBIT -49 461.2 kDKK FY 2025 -6.8% vs 2024
Net debt -11 776.1 kDKK FY 2025 +78.8% vs 2024
Quick ratio 4.0 FY 2025 -7.2 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -31 975.16 | -98 763.65 | -61 547.81 | -39 132.58 | -42 198.71 |
| Employee benefit expenses | -4 987.06 | -8 079.39 | -8 546.22 | -7 177.85 | -7 262.47 |
| EBIT | -36 962.22 | - 106 843.04 | -70 094.02 | -46 310.42 | -49 461.17 |
| Other financial income | 1 705.52 | 4 475.34 | 587.51 | 1 697.99 | 473.42 |
| Other financial expenses | - 292.26 | -1 525.89 | - 512.95 | - 149.27 | - 312.25 |
| Pre-tax profit | -35 548.96 | - 103 893.59 | -70 019.47 | -44 761.70 | -49 300.01 |
| Income taxes | 5 795.70 | 5 500.00 | 5 500.00 | 5 500.00 | 5 500.00 |
| Net earnings | -29 753.26 | -98 393.59 | -64 519.47 | -39 261.70 | -43 800.01 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | 99.98 | 81.21 | 139.98 | 146.98 | 154.33 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current owed by particip. interest comp. | 1 781.77 | ||||
| Prepayments and accrued income | 116.55 | 193.92 | 182.78 | 236.53 | 63.75 |
| Current other receivables | 34 598.21 | 6 475.28 | 2 462.43 | 1 364.71 | 465.10 |
| Current deferred tax assets | 5 500.00 | 7 194.51 | 5 500.00 | 5 500.00 | 5 500.00 |
| Short term receivables total | 41 996.53 | 13 863.71 | 8 145.21 | 7 101.24 | 6 028.85 |
| Cash and bank deposits | 74 117.51 | 54 920.33 | 65 641.42 | 55 637.83 | 11 779.80 |
| Cash and cash equivalents | 74 117.51 | 54 920.33 | 65 641.42 | 55 637.83 | 11 779.80 |
| Balance sheet total (assets) | 116 214.03 | 68 865.25 | 73 926.61 | 62 886.05 | 17 962.97 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 199.78 | 244.01 | 326.56 | 357.29 | 357.29 |
| Retained earnings | 136 359.52 | 149 366.59 | 130 889.99 | 96 177.96 | 56 916.27 |
| Profit of the financial year | -29 753.26 | -98 393.59 | -64 519.47 | -39 261.70 | -43 800.01 |
| Shareholders equity total | 106 806.04 | 51 217.01 | 66 697.07 | 57 273.56 | 13 473.55 |
| Non-current liabilities total | |||||
| Current trade creditors | 8 235.42 | 17 309.17 | 6 690.44 | 4 638.32 | 3 626.19 |
| Current owed to participating | 1.35 | 1.77 | 1.77 | 3.68 | |
| Other non-interest bearing current liabilities | 1 172.57 | 337.72 | 537.33 | 972.41 | 859.55 |
| Current liabilities total | 9 407.99 | 17 648.24 | 7 229.54 | 5 612.49 | 4 489.43 |
| Balance sheet total (liabilities) | 116 214.03 | 68 865.25 | 73 926.61 | 62 886.05 | 17 962.97 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated